The models can help find better inhibitors for conditions like baldness and prostate disorders.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Quercetin and kaempferol may be effective and safe natural treatments for hair loss.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Quercetin and kaempferol may be effective and safe natural treatments for hair loss.
June 2026 in “The Journal of Sexual Medicine” Finasteride may be linked to more psychiatric issues than dutasteride, but a definite cause isn't proven.
June 2026 in “British Journal of Dermatology” Finasteride mildly affects semen but is reversible; dutasteride has stronger effects with incomplete recovery.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
Finasteride and dutasteride can harm male reproductive health, affecting sperm and causing sexual dysfunction.
April 2026 in “Journal of the American Academy of Dermatology” Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
March 2026 in “Tropical Journal of Natural Product Research” Albizia saponaria bark extract may help treat hair loss.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
January 2026 in “Clinical Chemistry and Laboratory Medicine (CCLM)” The procedure accurately measures 5-alpha-dihydrotestosterone in blood, useful for standard tests.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “Journal of the American Academy of Dermatology” 5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Open Science Framework” Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
November 2025 in “ACS Omega” Teak leaf extract may help hair growth and reduce inflammation safely.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
October 2025 in “International Journal of Cosmetic Science” USPlus® DERM may help hair growth and reduce hair loss.
October 2025 in “Journal of the Endocrine Society” Finasteride lowers cholesterol but doesn't reduce heart-related events.
September 2025 in “Consilium Medicum” 5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
July 2025 in “Biotechnology and Bioprocess Engineering” Spirulina extract may effectively promote hair growth and reduce inflammation, offering a natural alternative for hair loss treatment.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.